Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Status:
Not yet recruiting
Trial end date:
2024-12-06
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to look at how safe and useful a drug called
azacitidine in combination with a drug called venetoclax, is in people with accelerated or
blast phase BRC-ABL negative myeloproliferative neoplasms.